{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:52:03Z","timestamp":1770976323239,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bbrep.2021.101032","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T09:02:35Z","timestamp":1622710955000},"page":"101032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-7906","authenticated-orcid":false,"given":"Ibrahim","family":"Khater","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-9387","authenticated-orcid":false,"given":"Aaya","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2021.101032_bib1","series-title":"StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing","article-title":"Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Updated 2021 Apr 20]","author":"Cascella","year":"2021"},{"key":"10.1016\/j.bbrep.2021.101032_bib2","first-page":"1","article-title":"Pneumonia of unknown etiology in Wuhan, China: potential for International spread via commercial air travel","author":"Bogoch","year":"2020","journal-title":"J. Trav. Med."},{"key":"10.1016\/j.bbrep.2021.101032_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-NCoV epidemic threat of novel coronaviruses to global health \u2014 the latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bbrep.2021.101032_bib4","series-title":"COVID-19 CORONAVIRUS PANDEMIC","author":"Worldometer","year":"2020"},{"key":"10.1016\/j.bbrep.2021.101032_bib5","series-title":"From SARS and MERS to COVID-19\u00a0: A Brief Summary and Comparison of Severe Acute Respiratory Infections Caused by Three Highly Pathogenic Human Coronaviruses","first-page":"1","author":"Zhu","year":"2020"},{"issue":"2","key":"10.1016\/j.bbrep.2021.101032_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"issue":"10224","key":"10.1016\/j.bbrep.2021.101032_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbrep.2021.101032_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jmv.25689","article-title":"Updated understanding of the outbreak of 2019 novel coronavirus (2019-NCoV) in Wuhan, China","volume":"92","author":"Wang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bbrep.2021.101032_bib9","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected Pneumonia","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.bbrep.2021.101032_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbrep.2021.101032_bib11","article-title":"Identification of a novel coronavirus causing severe Pneumonia in human","volume":"1","author":"Ren","year":"2020","journal-title":"Chinese Med J"},{"issue":"4","key":"10.1016\/j.bbrep.2021.101032_bib12","first-page":"P7","article-title":"Novel Wuhan (2019-NCoV) coronavirus","volume":"201","author":"Graham Carlos","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"June","key":"10.1016\/j.bbrep.2021.101032_bib13","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbrep.2021.101032_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV Nsp12 polymerase bound to Nsp 7 and Nsp 8 Co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.bbrep.2021.101032_bib15","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1093\/nar\/gkv838","article-title":"Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all Nidoviruses","volume":"43","author":"Lehmann","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.bbrep.2021.101032_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/fvl-2017-0027","article-title":"Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor","volume":"12","author":"Elfiky","year":"2017","journal-title":"Future Virol."},{"key":"10.1016\/j.bbrep.2021.101032_bib17","series-title":"Identification of Novel Proteolytically Inactive Mutations in Coronavirus 3C-like Protease Using a Combined Approach","first-page":"1","author":"Zhou","year":"2019"},{"key":"10.1016\/j.bbrep.2021.101032_bib18","first-page":"1","article-title":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach","author":"Khan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"17","key":"10.1016\/j.bbrep.2021.101032_bib19","doi-asserted-by":"crossref","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.bbrep.2021.101032_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrep.2021.101032_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbrep.2021.101032_bib22","first-page":"695","volume":"29","author":"Clercq","year":"2016"},{"key":"10.1016\/j.bbrep.2021.101032_bib23","series-title":"Review Clinical Trials of Antiviral Agents","first-page":"97","author":"Morris","year":"1992"},{"issue":"4","key":"10.1016\/j.bbrep.2021.101032_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/pathogens8040176","article-title":"Direct-acting antiviral agents for HCV-associated glomerular disease and the current evidence","volume":"8","author":"Fabrizi","year":"2019","journal-title":"Pathogens"},{"issue":"November","key":"10.1016\/j.bbrep.2021.101032_bib25","doi-asserted-by":"crossref","first-page":"173430","DOI":"10.1016\/j.ejphar.2020.173430","article-title":"In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2","volume":"886","author":"Deshpande","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbrep.2021.101032_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-NCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bbrep.2021.101032_bib27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5114\/aoms.2020.94567","article-title":"State-of-the-Art tools unveil potent drug targets amongst clinically approved drugs to inhibit Helicase in SARS-CoV-2","volume":"16","author":"Borgio","year":"2020","journal-title":"Arch. Med. Sci."},{"issue":"10","key":"10.1016\/j.bbrep.2021.101032_bib28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.chembiol.2004.08.011","article-title":"High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase","volume":"11","author":"Blanchard","year":"2004","journal-title":"Chem. Biol."},{"issue":"18","key":"10.1016\/j.bbrep.2021.101032_bib29","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"issue":"May","key":"10.1016\/j.bbrep.2021.101032_bib30","first-page":"1","article-title":"Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors","author":"Bhardwaj","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrep.2021.101032_bib31","doi-asserted-by":"crossref","first-page":"104117","DOI":"10.1016\/j.compbiomed.2020.104117","article-title":"Evaluation of Acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs","volume":"128","author":"Bhardwaj","year":"2021","journal-title":"Comput. Biol. Med."},{"issue":"10","key":"10.1016\/j.bbrep.2021.101032_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240079","article-title":"Biochemical screening for SARS-CoV-2 main protease inhibitors","volume":"15","author":"Coelho","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.bbrep.2021.101032_bib33","first-page":"1","article-title":"In-silico homology assisted identification of inhibitor of RNA binding against 2019-NCoV N- protein ( N terminal domain )","author":"Sarma","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"7594","key":"10.1016\/j.bbrep.2021.101032_bib34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in Rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bbrep.2021.101032_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bbrep.2021.101032_bib36","series-title":"Nelfinavir was Predicted to Be a Potential Inhibitor of 2019-NCov Main Protease by an Integrative Approach Combining Homology Modelling , Molecular Docking and Binding Free Energy Calculation","volume":"1201","author":"Xu","year":"2020"},{"issue":"23","key":"10.1016\/j.bbrep.2021.101032_bib37","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bbrep.2021.101032_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"3","key":"10.1016\/j.bbrep.2021.101032_bib39","first-page":"154","article-title":"Direct-acting antiviral medications for chronic Hepatitis C virus infection","volume":"7","author":"Jazwinski","year":"2011"},{"issue":"November 2017","key":"10.1016\/j.bbrep.2021.101032_bib40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0\u00a0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrep.2021.101032_bib41","series-title":"Avogadro: an Advanced Semantic Chemical Editor, Visualization, and Analysis Platform","first-page":"1","author":"Hanwell","year":"2012"},{"issue":"6489","key":"10.1016\/j.bbrep.2021.101032_bib42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbrep.2021.101032_bib43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microb. Infect."},{"issue":"7","key":"10.1016\/j.bbrep.2021.101032_bib44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"Pronk","year":"2013","journal-title":"Bioinformatics"},{"issue":"27","key":"10.1016\/j.bbrep.2021.101032_bib45","doi-asserted-by":"crossref","first-page":"14047","DOI":"10.1039\/C4CP01378F","article-title":"Performance of the MM\/GBSA scoring using a binding site hydrogen bond network-based frame selection: the protein kinase case","volume":"16","author":"Adasme-Carre\u00f1o","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"50","key":"10.1016\/j.bbrep.2021.101032_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and Cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrep.2021.101032_bib47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3389\/fmolb.2020.616341","article-title":"Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19","volume":"7","author":"Cui","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"53","key":"10.1016\/j.bbrep.2021.101032_bib48","doi-asserted-by":"crossref","first-page":"32148","DOI":"10.1039\/D0RA05679K","article-title":"Inhibition of SARS-CoV-2 main protease by phenolic compounds from Manilkara Hexandra (Roxb.) Dubard assisted by metabolite profiling and in silico virtual screening","volume":"10","author":"Abd El-Mordy","year":"2020","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bbrep.2021.101032_bib49","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/s41598-020-62423-y","article-title":"Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations","volume":"10","author":"Badaya","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bbrep.2021.101032_bib50","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.bbrep.2021.101032_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1359-0278(98)00019-4","article-title":"What is the probability of a chance prediction of a protein structure with an Rmsd of 6 \u00c5?","volume":"3","author":"Reva","year":"1998","journal-title":"Folding Des."},{"issue":"2","key":"10.1016\/j.bbrep.2021.101032_bib52","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/viro.1993.1419","article-title":"Nucleotide sequence of the human coronavirus 229E RNA polymerase locus","volume":"195","author":"Herold","year":"1993","journal-title":"Virology"},{"issue":"44","key":"10.1016\/j.bbrep.2021.101032_bib53","doi-asserted-by":"crossref","first-page":"27381","DOI":"10.1073\/pnas.2010470117","article-title":"Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs","volume":"117","author":"Li","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"212","key":"10.1016\/j.bbrep.2021.101032_bib54","first-page":"399","article-title":"The era of direct-acting antivirals has Begun\u00a0: the beginning of the end for HCV\u00a0?","volume":"1","author":"Vachon","year":"2011"}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580821001266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580821001266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:44:31Z","timestamp":1762501471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580821001266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":54,"alternative-id":["S2405580821001266"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2021.101032","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2021.101032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101032"}}